Sodium borohydride → 3-[3'-Hydroxymethyl-1-methyl-5-(5-methyl-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazin-2-ylamino)-6-oxo-1,6-dihydro-[3,4']bipyridinyl-2'-yl]-6,7,8,9-tetrahydro-3H-benzo[4,5]thieno[2,3-d]pyridazin-4-one

HRID 1021831Notes

Reaction equation

HRID 1021831 reaction equation
[CH3:1][N:2]1[C:7](=[O:8])[C:6]([NH:9][C:10]2[CH:19]=[C:13]3[CH2:14][N:15]([CH3:18])[CH2:16][CH2:17][N:12]3[N:11]=2)=[CH:5][C:4]([C:20]2[CH:25]=[CH:24][N:23]=[C:22]([N:26]3[C:38](=[O:39])[C:37]4[S:36][C:35]5[CH2:34][CH2:33][CH2:32][CH2:31][C:30]=5[C:29]=4[CH:28]=[N:27]3)[C:21]=2[CH:40]=[O:41])=[CH:3]1.[BH4-].[Na+]>CO>[OH:41][CH2:40][C:21]1[C:22]([N:26]2[C:38](=[O:39])[C:37]3[S:36][C:35]4[CH2:34][CH2:33][CH2:32][CH2:31][C:30]=4[C:29]=3[CH:28]=[N:27]2)=[N:23][CH:24]=[CH:25][C:20]=1[C:4]1[CH:5]=[C:6]([NH:9][C:10]2[CH:19]=[C:13]3[CH2:14][N:15]([CH3:18])[CH2:16][CH2:17][N:12]3[N:11]=2)[C:7](=[O:8])[N:2]([CH3:1])[CH:3]=1

Participants

4

Conditions

Temperature
30 °C

Procedure

A mixture of 181a (300 mg, 0.50 mmol) and NaBH4 (60 mg, 1.5 mmol) in methanol (20 mL) was stirred at 30° C. for 1 h. The mixture was quenched with water and concentrated under reduced pressure. The residue was extracted with ethyl acetate (3×10 mL). The combined ethyl acetate extract was concentrated under reduced pressure and the residue was purified by reverse-phase prep-HPLC to afford 181 (100 mg, 35%). MS-ESI: [M+H]+ 571.2. 1H NMR (500 MHz, CHCl3) δ 8.64 (d, J=5.0 Hz, 1H), 8.30 (s, 1H), 8.00 (d, J=2.0 Hz, 1H), 7.57 (d, J=2.0 Hz, 1H), 7.53 (d, J=5.0 Hz, 1H), 7.43 (s, 1H), 5.70 (s, 1H), 4.45-4.43 (m, 2H), 4.32 (bs, 1H), 4.11-4.09 (m, 2H), 3.71 (s, 3H), 3.63 (s, 2H), 2.99-2.97 (m, 2H), 2.93-2.91 (m, 2H), 2.88-2.86 (m, 2H), 2.50 (s, 3H), 2.00-1.98 (m, 4H).

Workup

  1. customThe mixture was quenched with water
  2. concentrationconcentrated under reduced pressure
  3. extractionThe residue was extracted with ethyl acetate (3×10 mL)
  4. extractionThe combined ethyl acetate extract
  5. concentrationwas concentrated under reduced pressure
  6. customthe residue was purified by reverse-phase prep-HPLC

Sources & evidence

ORD record
ord-397f4e67043943db8a734c931886a122
Source dataset
uspto-grants-2014_05
Patent number
US08716274B2

Reaction notes

Loading…